The preimplantation genetic testing market is anticipated to exhibit a compound annual growth rate (CAGR) of approximately 9% and is expected to achieve a remarkable valuation by the year 2032. This growth can be attributed to the expanding prevalence of genetic disorders, which is creating favorable opportunities for market expansion.
By the year 2022, it is projected that the market will attain a value of US$ 653.52 Million, and this upward trajectory is anticipated to continue, reaching a valuation of US$ 1,420 Million by 2032.
Preimplantation Genetic Testing (PGT) is a rapidly evolving sector in the field of reproductive medicine. It involves the examination of embryos before implantation to identify genetic abnormalities, ensuring the selection of healthy embryos for in vitro fertilization (IVF). The global Preimplantation Genetic Testing market has witnessed substantial growth in recent years, driven by advancements in genetic technologies, rising awareness about genetic disorders, and increasing demand for assisted reproductive technologies.
The market is characterized by a surge in the number of couples opting for IVF procedures, owing to factors such as delayed pregnancies, rising infertility rates, and a growing focus on family planning. PGT plays a pivotal role in this landscape by providing a means to identify and mitigate the risk of genetic disorders, contributing to the overall success of IVF treatments.
Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=292
The dynamics of the Preimplantation Genetic Testing market are intricately linked to advancements in genetic technologies and a growing understanding of genetic disorders. The rising prevalence of genetic disorders and an increasing trend towards delayed parenthood contribute to the expanding market. PGT assists in the identification of genetic abnormalities in embryos, allowing for the selection of healthy embryos for implantation, ultimately reducing the risk of genetic diseases in newborns.
Moreover, a surge in infertility cases, coupled with the growing acceptance of in vitro fertilization (IVF) procedures, has augmented the demand for PGT. As the accessibility and affordability of genetic testing technologies improve, the market is poised for substantial growth. However, ethical concerns, regulatory challenges, and the high cost of PGT procedures may pose obstacles to market expansion.
Market Future Outlook:
The future outlook of the Preimplantation Genetic Testing market is optimistic, with a projected increase in demand for personalized and precise genetic screening. Advancements in next-generation sequencing technologies and the integration of artificial intelligence in genetic analysis are anticipated to enhance the accuracy and efficiency of PGT procedures.
Additionally, a growing emphasis on expanding the scope of genetic testing beyond traditional indications to include polygenic disorders and multifactorial traits is expected to drive market growth. The integration of PGT with other reproductive technologies, such as CRISPR-based gene editing, could further revolutionize the landscape of genetic screening.
The Preimplantation Genetic Testing market is segmented based on the type of genetic testing, including PGT-A (aneuploidy screening), PGT-M (monogenic/single gene disorders), and PGT-SR (structural rearrangements). PGT-A holds a significant market share, given its application in screening for chromosomal abnormalities, which is crucial for improving the success rates of IVF procedures.
Geographically, North America and Europe dominate the PGT market due to the high awareness levels, advanced healthcare infrastructure, and favorable reimbursement policies. However, the Asia-Pacific region is witnessing rapid growth, attributed to the increasing prevalence of infertility and a growing focus on healthcare infrastructure development.
- Agilent Technologies Inc.
- Abbott Laboratories
- CooperSurgical Inc.
- Oxford Gene Technology IP
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- PerkinElmer Inc.
- Genea Limited
- Natera Inc.
In May of 2021, United Airlines and Abbott Laboratories revealed a collaborative effort to utilize Abbott’s BinaxNOW™ COVID-19 Home Test and NAVICA app to enhance the international travel experience.
In March of 2021, Agilent Technologies Inc. entered into a definitive agreement to acquire Resolution Bioscience Inc., a leading developer and commercializer of next-generation sequencing (NGS)-based precision oncology solutions.
In June of 2021, Thermo Fisher Scientific and First Genetics JCS, a manufacturer of diagnostic equipment and IVD kits designed to advance molecular genetic technologies into clinical practice, announced a strategic partnership focused on commercializing next-generation sequencing (NGS)-based diagnostics in Russia. This agreement enables First Genetics to market its F-Genetics NGS System and IVD assays to Russian labs for reproductive health testing and cancer diagnostics, with the F-Genetics System being based on Thermo Fisher’s Ion GeneStudio S5 System.
Key Segments in Preimplantation Genetic Testing Industry Research
- By Test Type :
- By End User :
- Diagnostic Labs
- Research & Academic Institutions
- Specialized Clinics
- By Application :
- Embryo HLA Typing for Stem Cell Therapy
- IVF Prognosis
- Late-Onset Genetic Disorders
- Inherited Genetic Diseases
- By Technology :
- By Region :
- North America
- Latin America
- Middle East Africa
Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=292
About Fact.MR :
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
US Sales Office
11140 Rockville Pike
Suite 400 Rockville, MD 20852
United States Tel: +1 (628) 251–1583, +353–1–4434–232 (D)
Sales Team: firstname.lastname@example.org